Elranatamab is a humanized IgG2 bispecific T-cell inducing antibody that targets CD3 and B-cell maturation antigen (BCMA) on the surface of T-cells, resulting in activation of T-cells and the release of a variety of pro-inflammatory cytokines that lead to multiple myeloma cell lysis. It can be used in studies related to relapsed or refractory multiple myeloma (RRMM).
Purity:
>99.0%
CAS Number:
[2408850-14-4]
* VAT and and shipping costs not included. Errors and price changes excepted
